David J Wong, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 15
- 5 carriers
- Offices
- 5
Offices
5 locations · Stanford Health Care · Direct Dermatology Professionals PC
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
15 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wong’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A84286 · Current
Licensed to practise in California · since 2003 · expires 2026-12-31 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$170,330
Medicare paid this office $170,330 for 648 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 276 | $39,192 | $89 |
| Short return visit (20+ min) | 316 | $24,807 | $62 |
| Destruction of skin growth, 1-14 growths | 114 | $13,150 | $89 |
| Biopsy of related skin growth, first growth | 121 | $8,213 | $67 |
| Destruction of precancer skin growth, 1 growth | 132 | $7,137 | $42 |
See all 13 services
| Return visit (30+ min) | 276 | $39,192 | $89 |
| Short return visit (20+ min) | 316 | $24,807 | $62 |
| Destruction of skin growth, 1-14 growths | 114 | $13,150 | $89 |
| Biopsy of related skin growth, first growth | 121 | $8,213 | $67 |
| Destruction of precancer skin growth, 1 growth | 132 | $7,137 | $42 |
| New patient visit (30+ min) | 85 | $5,941 | $70 |
| New patient visit (45+ min) | 43 | $4,649 | $108 |
| Destruction of precancer skin growth, 15 or more growths | 23 | $3,916 | $126 |
| Punch biopsy, first skin growth | 29 | $3,044 | $101 |
| Destruction of precancer skin growth, 2-14 growths | 90 | $2,345 | $5 |
| Biopsy of related skin growth, each additional growth | 25 | $1,245 | $42 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 13 | $347 | $20 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $24 | None |
Procedures Medicare counted
| Removal of nail tissue | 1-10 | None |
| Removal of skin lesions | 681 | More than 90% of doctors who do this |
| Removal or shaving of skin growth | 15 | More than 68% of doctors who do this |
| Skin biopsy | 275 | More than 89% of doctors who do this |
Who their Medicare patients are
648 Original Medicare patients in 2024. Average age 68 · Under 65 22% · 85 and older 8% · Women 55% · Also on Medicaid 78% · Health risk score 1.29. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 71% · Diabetes 38% · Chronic kidney disease 23% · Depression 23% · Coronary heart disease 20% · COPD 15% · Heart failure 13% · Atrial fibrillation 12% · Cancer 10% · Stroke 8% · Dementia 6%.
The office billed $509,972, Medicare allowed $235,627 and paid $170,330; for 2,457 services of 28 kinds; $24 of it was for drugs given in the office and $170,306 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 648 | 2,457 | 68 | 1.29 | $509,972 | $170,330 |
| 2023 | 522 | 1,896 | 68 | 1.20 | $331,604 | $100,548 |
| 2022 | 632 | 1,885 | 67 | 1.26 | $307,736 | $87,090 |
| 2021 | 873 | 2,748 | 67 | 1.24 | $448,278 | $128,676 |
| 2020 | 602 | 1,772 | 67 | 1.35 | $300,829 | $74,166 |
| 2019 | 346 | 1,202 | 67 | 1.37 | $190,363 | $53,078 |
| 2018 | 237 | 1,040 | 66 | 1.33 | $145,946 | $38,030 |
| 2017 | 168 | 780 | 66 | 1.19 | $93,519 | $24,371 |
| 2016 | 107 | 514 | 67 | 1.17 | $58,201 | $15,370 |
| 2015 | 134 | 508 | 71 | 1.29 | $55,807 | $15,944 |
| 2014 | 37 | 201 | 74 | 1.16 | $25,148 | $4,933 |
| 2013 | 50 | 180 | 74 | 1.63 | $18,319 | $5,268 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Short return visit (20+ min) | 323 | $28,066 | $61 |
| Return visit (30+ min) | 177 | $22,759 | $88 |
| Destruction of skin growth, 1-14 growths | 103 | $12,078 | $86 |
| Biopsy of related skin growth, first growth | 100 | $7,228 | $66 |
| Destruction of precancer skin growth, 1 growth | 115 | $5,986 | $41 |
| Destruction of precancer skin growth, 15 or more growths | 21 | $3,174 | $122 |
| Punch biopsy, first skin growth | 29 | $2,960 | $99 |
| Destruction of skin growth, 15 or more growths | 16 | $2,394 | $96 |
| Destruction of precancer skin growth, 2-14 growths | 81 | $2,134 | $4 |
| New patient visit (45+ min) | 15 | $1,734 | $116 |
| New patient visit (30+ min) | 19 | $1,322 | $70 |
| Biopsy of related skin growth, each additional growth | 24 | $1,192 | $40 |
| Injection into skin growth, 1-7 growths | 11 | $805 | $40 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 26 | $676 | $22 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $26 | None |
2022: 12 services
| Short return visit (20+ min) | 405 | $31,156 | $55 |
| Return visit (30+ min) | 102 | $11,873 | $89 |
| Destruction of skin growth, 1-14 growths | 65 | $7,123 | $78 |
| Biopsy of related skin growth, first growth | 95 | $6,629 | $65 |
| Destruction of precancer skin growth, 1 growth | 94 | $4,964 | $41 |
| New patient visit (45+ min) | 51 | $4,692 | $92 |
| Destruction of precancer skin growth, 15 or more growths | 23 | $4,182 | $131 |
| New patient visit (30+ min) | 61 | $3,470 | $57 |
| New patient visit (15+ min) | 94 | $3,251 | $35 |
| Punch biopsy, first skin growth | 27 | $2,626 | $94 |
| Destruction of precancer skin growth, 2-14 growths | 74 | $2,140 | $4 |
| Biopsy of related skin growth, each additional growth | 22 | $1,051 | $35 |
2021: 15 services
| Short return visit (20+ min) | 535 | $46,370 | $59 |
| New patient visit (30+ min) | 194 | $12,582 | $65 |
| Return visit (30+ min) | 110 | $12,509 | $89 |
| Destruction of skin growth, 1-14 growths | 110 | $11,854 | $86 |
| Biopsy of related skin growth, first growth | 128 | $10,242 | $71 |
| Destruction of precancer skin growth, 1 growth | 131 | $6,477 | $37 |
| Destruction of precancer skin growth, 15 or more growths | 36 | $5,944 | $119 |
| New patient visit (15+ min) | 145 | $5,348 | $37 |
| Punch biopsy, first skin growth | 39 | $4,374 | $102 |
| Destruction of precancer skin growth, 2-14 growths | 97 | $3,750 | $5 |
| New patient visit (45+ min) | 25 | $2,525 | $101 |
| Biopsy of related skin growth, each additional growth | 30 | $1,931 | $43 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 22 | $759 | $29 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 19 | $294 | $12 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 18 | $26 | None |
2020: 14 services
| Short return visit (20+ min) | 393 | $28,274 | $47 |
| Destruction of skin growth, 1-14 growths | 88 | $9,636 | $76 |
| Biopsy of related skin growth, first growth | 111 | $7,448 | $64 |
| New patient visit (15+ min) | 131 | $5,477 | $42 |
| Destruction of precancer skin growth, 1 growth | 100 | $4,463 | $37 |
| Destruction of precancer skin growth, 15 or more growths | 27 | $4,106 | $111 |
| New patient visit (30+ min) | 68 | $3,615 | $53 |
| Return visit (30+ min) | 34 | $3,487 | $71 |
| Destruction of precancer skin growth, 2-14 growths | 67 | $1,720 | $4 |
| Punch biopsy, first skin growth | 14 | $1,243 | $83 |
| Biopsy of related skin growth, each additional growth | 24 | $1,002 | $42 |
| Injection into skin growth, 1-7 growths | 13 | $794 | $36 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 14 | $358 | $24 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $20 | None |
2019: 10 services
| Short return visit (20+ min) | 303 | $23,161 | $52 |
| Destruction of skin growth, 1-14 growths | 69 | $8,118 | $84 |
| Biopsy of related skin growth, first growth | 100 | $7,128 | $69 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $2,875 | $115 |
| Destruction of precancer skin growth, 1 growth | 62 | $2,799 | $38 |
| Punch biopsy, first skin growth | 23 | $2,257 | $98 |
| Return visit (30+ min) | 17 | $1,784 | $78 |
| Destruction of precancer skin growth, 2-14 growths | 49 | $1,317 | $4 |
| Biopsy of related skin growth, each additional growth | 26 | $1,182 | $41 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $16 | None |
2018: 8 services
| Short return visit (20+ min) | 222 | $16,587 | $49 |
| Destruction of skin growth, 1-14 growths | 46 | $5,328 | $77 |
| Biopsy of single growth of skin and/or tissue | 63 | $5,275 | $72 |
| Destruction of precancer skin growth, 1 growth | 55 | $2,933 | $39 |
| Destruction of precancer skin growth, 15 or more growths | 19 | $2,639 | $98 |
| Return visit (30+ min) | 17 | $1,367 | $72 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $1,337 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 15 | $546 | $25 |
2017: 6 services
| Short return visit (20+ min) | 163 | $11,657 | $48 |
| Biopsy of single growth of skin and/or tissue | 52 | $4,054 | $69 |
| Destruction of skin growth, 1-14 growths | 37 | $3,269 | $80 |
| Destruction of precancer skin growth, 1 growth | 39 | $1,913 | $35 |
| Destruction of precancer skin growth, 2-14 growths | 31 | $1,253 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 17 | $614 | $25 |
2016: 6 services
| Short return visit (20+ min) | 97 | $6,434 | $46 |
| Destruction of skin growth, 1-14 growths | 30 | $2,835 | $77 |
| Biopsy of single growth of skin and/or tissue | 28 | $1,664 | $57 |
| Destruction of precancer skin growth, 1 growth | 30 | $1,645 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $803 | $4 |
| Biopsy of each additional growth of skin and/or tissue | 13 | $406 | $25 |
2015: 9 services
| Short return visit (20+ min) | 38 | $3,162 | $55 |
| Short return visit (20+ min) | 47 | $3,017 | $42 |
| New patient visit (30+ min) | 14 | $1,103 | $79 |
| Biopsy of single growth of skin and/or tissue | 13 | $1,072 | $82 |
| Destruction of precancer skin growth, 1 growth | 19 | $907 | $41 |
| New patient visit (15+ min) | 14 | $821 | $59 |
| Destruction of precancer skin growth, 1 growth | 11 | $735 | $49 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $456 | $5 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $232 | $2 |
2014: 3 services
| Short return visit (20+ min) | 31 | $2,091 | $43 |
| Destruction of precancer skin growth, 1 growth | 18 | $1,003 | $42 |
| Destruction of precancer skin growth, 2-14 growths | 14 | $177 | $2 |
2013: 1 service
| Short return visit (20+ min) | 41 | $2,646 | $38 |
Medicaid work
$1,030,288 in 2024
Medicaid paid $1,030,288 for 16,282 billed services this clinician did in 2024, up to 621 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 4,426 | $245,130 |
| Excimer laser treatment for psoriasis; over 500 sq cm | 845 | $179,939 |
| Short return visit (20+ min) | 3,650 | $134,107 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 1,425 | $114,543 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 1,023 | $75,132 |
| Excimer laser treatment for psoriasis; total area less than 250 sq cm | 1,049 | $67,500 |
| Excimer laser treatment for psoriasis; 250 sq cm to 500 sq cm | 463 | $50,041 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 545 | $43,176 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 249 | $22,442 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 652 | $19,467 |
| New patient visit (45+ min) | 170 | $16,340 |
| New patient visit (30+ min) | 265 | $15,891 |
| 2024 | 16,282 | 22 | 621 | $1,030,288 |
| 2023 | 15,732 | 18 | 475 | $569,019 |
| 2022 | 14,335 | 18 | 591 | $494,420 |
| 2021 | 20,506 | 20 | 706 | $833,835 |
| 2020 | 15,058 | 18 | 687 | $589,671 |
| 2019 | 16,462 | 17 | 798 | $650,299 |
| 2018 | 13,150 | 16 | 671 | $672,572 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 3,745 | $143,296 |
| Short return visit (20+ min) | 4,325 | $122,898 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 1,826 | $95,415 |
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 620 | $51,085 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 674 | $32,228 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 622 | $25,146 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 264 | $18,151 |
| Excimer laser treatment for psoriasis; total area less than 250 sq cm | 150 | $16,786 |
| Injection, intralesional; up to and including 7 lesions | 556 | $12,721 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions | 230 | $10,500 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion | 369 | $9,838 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 568 | $9,182 |
2022
| Short return visit (20+ min) | 5,124 | $124,501 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 1,496 | $93,089 |
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 1,083 | $84,851 |
| Return visit (30+ min) | 1,938 | $70,001 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 593 | $27,784 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 379 | $14,640 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 725 | $13,300 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions | 218 | $11,695 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 240 | $10,800 |
| Injection, intralesional; up to and including 7 lesions | 368 | $8,897 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion | 310 | $8,174 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 515 | $8,169 |
2021
| Short return visit (20+ min) | 7,034 | $188,179 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 2,203 | $165,463 |
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 2,130 | $164,000 |
| Return visit (30+ min) | 1,868 | $84,534 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 1,415 | $62,485 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 721 | $39,312 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 1,220 | $29,989 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions | 242 | $22,320 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 306 | $17,558 |
| New patient visit (30+ min) | 248 | $12,477 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion | 440 | $11,384 |
| Injection, intralesional; up to and including 7 lesions | 557 | $10,862 |
2020
| Short return visit (20+ min) | 6,458 | $159,279 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 2,124 | $155,993 |
| Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | 579 | $48,985 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 944 | $48,877 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 781 | $45,561 |
| Return visit (30+ min) | 707 | $41,758 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions | 301 | $21,325 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 196 | $15,418 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion | 369 | $11,215 |
| New patient visit (30+ min) | 210 | $9,581 |
| Injection, intralesional; up to and including 7 lesions | 517 | $9,320 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 584 | $5,781 |
2019
| Short return visit (20+ min) | 7,536 | $194,536 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 2,410 | $188,531 |
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 886 | $66,817 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 1,022 | $50,099 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 549 | $29,244 |
| Punch biopsy of skin (including simple closure, when performed); single lesion | 338 | $27,223 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions | 296 | $26,226 |
| Return visit (30+ min) | 366 | $17,389 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion | 392 | $12,928 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 572 | $9,453 |
| Injection, intralesional; up to and including 7 lesions | 572 | $9,027 |
| Injection, intralesional; more than 7 lesions | 221 | $5,616 |
2018
| Short return visit (20+ min) | 6,386 | $236,629 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 2,132 | $211,155 |
| Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network | 882 | $71,994 |
| Service | 964 | $37,008 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 389 | $22,408 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions | 182 | $19,930 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 397 | $17,164 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion | 264 | $16,054 |
| Return visit (30+ min) | 263 | $14,842 |
| Injection, intralesional; up to and including 7 lesions | 338 | $8,107 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); second through 14 lesions, each (List separately in addition to code for first lesion) | 179 | $4,807 |
| Injection, intralesional; more than 7 lesions | 114 | $3,990 |
Drugs they prescribed that Part D paid
$1,904,840
Pharmacies billed $1,904,840 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,057) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
796 generic and 261 brand-name prescriptions · $1,904,840 in drug cost · 24 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Humira(Cf) | 66 | $520,895 | $7,892 |
| Skyrizi | 22 | $441,165 | $20,053 |
| Dupixent | 74 | $277,774 | $3,754 |
| Tremfya | 15 | $198,619 | $13,241 |
| Taltz | 23 | $150,145 | $6,528 |
See all 21 drugs
| Humira(Cf) | 66 | $520,895 | $7,892 |
| Skyrizi | 22 | $441,165 | $20,053 |
| Dupixent | 74 | $277,774 | $3,754 |
| Tremfya | 15 | $198,619 | $13,241 |
| Taltz | 23 | $150,145 | $6,528 |
| Otezla | 22 | $102,263 | $4,648 |
| Dupixent | 12 | $44,361 | $3,697 |
| Clobetasol Propionate | 82 | $6,416 | $78 |
| Betamethasone Diprop Augmented | 51 | $3,148 | $62 |
| Calcipotriene | 12 | $2,189 | $182 |
| Fluocinonide | 57 | $2,002 | $35 |
| Halobetasol Propionate | 34 | $1,972 | $58 |
| Ketoconazole | 97 | $1,579 | $16 |
| Clindamycin Phosphate | 33 | $1,322 | $40 |
| Triamcinolone Acetonide | 121 | $1,033 | $9 |
| Metronidazole | 13 | $501 | $39 |
| Hydroxyzine | 36 | $434 | $12 |
| Hydrocortisone | 72 | $348 | $5 |
| Mupirocin | 23 | $178 | $8 |
| Clotrimazole | 18 | $163 | $9 |
| Prednisone | 19 | $116 | $6 |
Year by year
| 2024 | 1,057 | 241 | 0% (0) | 25% | $1,904,840 |
| 2023 | 843 | 215 | 0% (0) | 14% | $899,423 |
| 2022 | 1,313 | 329 | None | None | $673,827 |
| 2021 | 603 | 154 | 0% (0) | None | $487,134 |
| 2020 | 486 | 126 | 0% (0) | None | $307,957 |
| 2019 | 295 | 100 | 0% (0) | 21% | $135,313 |
| 2018 | 182 | 64 | 0% (0) | 16% | $54,338 |
| 2017 | 198 | 64 | 0% (0) | 17% | $156,890 |
| 2016 | 161 | 55 | None | None | $85,617 |
| 2015 | 205 | 57 | None | None | $52,334 |
| 2014 | 192 | 51 | None | 15% | $53,528 |
| 2013 | 261 | 115 | 0% (0) | 20% | $56,726 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Skyrizi | 20 | $428,379 | $21,419 |
| Dupixent | 36 | $139,306 | $3,870 |
| Clobetasol Propionate | 92 | $15,122 | $164 |
| Tacrolimus | 19 | $4,789 | $252 |
| Acitretin | 11 | $3,772 | $343 |
| Betamethasone Diprop Augmented | 44 | $3,532 | $80 |
| Metronidazole | 27 | $3,080 | $114 |
| Halobetasol Propionate | 22 | $2,901 | $132 |
| Fluocinonide | 37 | $2,814 | $76 |
| Fluorouracil | 15 | $1,906 | $127 |
| Triamcinolone Acetonide | 104 | $1,580 | $15 |
| Ketoconazole | 86 | $1,554 | $18 |
| Clindamycin Phosphate | 40 | $1,429 | $36 |
| Doxycycline Hyclate | 11 | $842 | $77 |
| Hydroxyzine | 36 | $772 | $21 |
| Hydrocortisone | 58 | $536 | $9 |
| Mupirocin | 18 | $308 | $17 |
2022: 24 drugs
| Humira(Cf) | 20 | $137,404 | $6,870 |
| Cosentyx Pen (2 Pens) | 12 | $102,370 | $8,531 |
| Dupixent | 23 | $86,566 | $3,764 |
| Clobetasol Propionate | 113 | $22,681 | $201 |
| Betamethasone Diprop Augmented | 59 | $6,892 | $117 |
| Tacrolimus | 18 | $5,046 | $280 |
| Metronidazole | 34 | $4,217 | $124 |
| Triamcinolone Acetonide | 265 | $3,905 | $15 |
| Fluocinonide | 52 | $3,751 | $72 |
| Betamethasone Dipropionate | 29 | $3,260 | $112 |
| Clindamycin Phosphate | 51 | $2,587 | $51 |
| Ketoconazole | 80 | $2,300 | $29 |
| Doxycycline Monohydrate | 29 | $2,281 | $79 |
| Halobetasol Propionate | 14 | $2,150 | $154 |
| Fluocinolone Acetonide | 14 | $1,608 | $115 |
| Hydroxyzine | 98 | $1,150 | $12 |
| Hydrocortisone | 130 | $911 | $7 |
| Mometasone Furoate | 17 | $761 | $45 |
| Minocycline | 20 | $456 | $23 |
| Mupirocin | 27 | $407 | $15 |
| Methotrexate | 11 | $391 | $36 |
| Acyclovir | 14 | $224 | $16 |
| Prednisone | 13 | $175 | $13 |
| Spironolactone | 11 | $123 | $11 |
2021: 13 drugs
| Humira(Cf) | 30 | $190,201 | $6,340 |
| Tremfya | 13 | $163,881 | $12,606 |
| Clobetasol Propionate | 47 | $3,808 | $81 |
| Metronidazole | 26 | $2,828 | $109 |
| Triamcinolone Acetonide | 94 | $1,679 | $18 |
| Ketoconazole | 49 | $1,078 | $22 |
| Hydroxyzine | 56 | $1,025 | $18 |
| Fluocinonide | 19 | $968 | $51 |
| Betamethasone Diprop Augmented | 19 | $635 | $33 |
| Prednisone | 32 | $575 | $18 |
| Doxycycline Monohydrate | 12 | $542 | $45 |
| Hydrocortisone | 38 | $241 | $6 |
| Hydroxyzine Pamoate | 14 | $57 | $4 |
2020: 12 drugs
| Humira(Cf) | 25 | $146,717 | $5,869 |
| Fluocinonide | 32 | $1,799 | $56 |
| Clobetasol Propionate | 28 | $1,764 | $63 |
| Triamcinolone Acetonide | 80 | $988 | $12 |
| Ketoconazole | 31 | $887 | $29 |
| Doxycycline Hyclate | 13 | $782 | $60 |
| Betamethasone Diprop Augmented | 18 | $689 | $38 |
| Clindamycin Phosphate | 14 | $632 | $45 |
| Hydroxyzine | 20 | $357 | $18 |
| Gabapentin | 12 | $303 | $25 |
| Prednisone | 19 | $220 | $12 |
| Hydrocortisone | 24 | $176 | $7 |
2019: 8 drugs
| Dexilant | 13 | $4,726 | $364 |
| Clindamycin Phosphate | 14 | $1,519 | $109 |
| Fluocinonide | 16 | $1,135 | $71 |
| Triamcinolone Acetonide | 30 | $702 | $23 |
| Ketoconazole | 24 | $396 | $17 |
| Hydroxyzine | 20 | $250 | $13 |
| Prednisone | 16 | $196 | $12 |
| Hydrocortisone | 12 | $79 | $7 |
2018: 1 drug
| Triamcinolone Acetonide | 30 | $373 | $12 |
2017: 3 drugs
| Humira | 11 | $55,017 | $5,002 |
| Clobetasol Propionate | 28 | $10,137 | $362 |
| Triamcinolone Acetonide | 47 | $758 | $16 |
2016: 3 drugs
| Clobetasol Propionate | 16 | $10,307 | $644 |
| Fluocinonide | 13 | $1,387 | $107 |
| Hydrocortisone | 12 | $83 | $7 |
2015: 5 drugs
| Clobetasol Propionate | 25 | $5,641 | $226 |
| Fluocinonide | 16 | $1,194 | $75 |
| Clindamycin Phosphate | 16 | $1,017 | $64 |
| Hydrocortisone | 17 | $656 | $39 |
| Triamcinolone Acetonide | 35 | $616 | $18 |
2014: 4 drugs
| Clobetasol Propionate | 33 | $2,083 | $63 |
| Hydrocortisone | 21 | $862 | $41 |
| Triamcinolone Acetonide | 22 | $555 | $25 |
| Ketoconazole | 14 | $293 | $21 |
2013: 7 drugs
| Metronidazole | 11 | $1,633 | $148 |
| Desonide | 22 | $1,210 | $55 |
| Clobetasol Propionate | 38 | $1,200 | $32 |
| Triamcinolone Acetonide | 27 | $841 | $31 |
| Fluocinonide | 21 | $617 | $29 |
| Hydroxyzine | 23 | $462 | $20 |
| Pantoprazole | 17 | $330 | $19 |
Money from drug and device companies
$812 in 2025
| 2025 | 16 | 39 | None | $812 |
| 2024 | 10 | 38 | None | $738 |
| 2023 | 6 | 39 | None | $690 |
| 2022 | 3 | 19 | None | $384 |
| 2021 | 2 | 22 | None | $342 |
| 2020 | 1 | 4 | None | $82 |
| 2019 | 2 | 4 | None | $70 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Skyrizi | $115 | 5 payments
|
| STRATA Skin Sciences | Xtrac | $87 | 9 payments
|
| Stryker | Augment Injectable | $82 | 1 payment
|
| Incyte | Opzelura | $62 | 4 payments
|
| Amgen | Otezla | $61 | 3 payments
|
| Organon | Vtama | $59 | 2 payments
|
See all 39 published payments
| STRATA Skin Sciences | Meals · 2025-12-22 | Xtrac | $11 |
| Novartis Pharmaceuticals | Meals · 2025-12-09 | Rhapsido | $35 |
| STRATA Skin Sciences | Meals · 2025-12-04 | Xtrac | $7 |
| Abbvie | Meals · 2025-11-19 | Skyrizi | $19 |
| Abbvie | Meals · 2025-11-07 | Skyrizi | $31 |
| Incyte | Meals · 2025-11-07 | Opzelura | $14 |
| Amgen | Meals · 2025-11-04 | Otezla | $23 |
| Arcutis Biotherapeutics | Meals · 2025-11-04 | Zoryve | $14 |
| Stryker | Meals · 2025-10-29 | Augment Injectable | $82 |
| Incyte | Meals · 2025-10-22 | Opzelura | $14 |
| Organon | Meals · 2025-10-21 | Vtama | $25 |
| Galderma Laboratories L.P. | Meals · 2025-10-08 | Nemluvio | $17 |
| Incyte | Meals · 2025-10-01 | Opzelura | $16 |
| Arcutis Biotherapeutics | Meals · 2025-09-30 | Zoryve | $14 |
| STRATA Skin Sciences | Meals · 2025-09-25 | Xtrac | $9 |
| Abbvie | Meals · 2025-09-11 | Skyrizi | $19 |
| Novartis Pharmaceuticals | Meals · 2025-08-26 | Xolair | $17 |
| STRATA Skin Sciences | Meals · 2025-08-21 | Xtrac | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-19 | Sotyktu | $21 |
| Amgen | Meals · 2025-07-15 | Otezla | $16 |
| Galderma Laboratories L.P. | Meals · 2025-07-09 | Nemluvio | $23 |
| STRATA Skin Sciences | Meals · 2025-06-19 | Xtrac | $7 |
| Verrica Pharmaceuticals | Meals · 2025-06-17 | Ycanth | $23 |
| Abbvie | Meals · 2025-06-04 | Skyrizi | $19 |
| Galderma Laboratories L.P. | Meals · 2025-05-21 | Nemluvio | $16 |
| STRATA Skin Sciences | Meals · 2025-05-13 | Xtrac | $10 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-02 | Sotyktu | $21 |
| STRATA Skin Sciences | Meals · 2025-04-02 | Xtrac | $9 |
| SpringWorks Therapeutics | Meals · 2025-03-14 | Gomekli | $29 |
| Almirall | Meals · 2025-03-05 | Klisyri | $28 |
| Amgen | Meals · 2025-02-18 | Otezla | $22 |
| STRATA Skin Sciences | Meals · 2025-02-11 | Xtrac | $12 |
| Incyte | Meals · 2025-02-08 | Opzelura | $17 |
| Ucb | Meals · 2025-02-05 | Bimzelx | $24 |
| MIMEDX Group | Meals · 2025-01-28 | None | $45 |
| Lilly USA | Meals · 2025-01-20 | Taltz | $20 |
| Abbvie | Meals · 2025-01-14 | Skyrizi | $26 |
| STRATA Skin Sciences | Meals · 2025-01-14 | Xtrac | $12 |
| Organon | Meals · 2025-01-09 | Vtama | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $738
| Ucb | Bimzelx | $164 | 9 payments
|
| Amgen | Otezla | $152 | 8 payments
|
| STRATA Skin Sciences | Xtrac | $105 | 8 payments
|
| Incyte | Opzelura | $90 | 4 payments
|
| Novartis Pharmaceuticals | Cosentyx | $66 | 2 payments
|
| Abbvie | Skyrizi | $66 | 3 payments
|
| Dermavant Sciences | Vtama | $29 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $24 | 1 payment
|
| Lilly USA | Taltz | $21 | 1 payment
|
| Verrica Pharmaceuticals | Ycanth | $21 | 1 payment
|
2023: $690
| STRATA Skin Sciences | Xtrac | $233 | 12 payments
|
| Amgen | Otezla | $157 | 8 payments
|
| Incyte | Opzelura | $144 | 13 payments
|
| Novartis Pharmaceuticals | Cosentyx | $111 | 4 payments
|
| AbbVie | Skyrizi | $30 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $384
| Abbvie | Humira | $164 | 10 payments
|
| Amgen | Otezla | $138 | 5 payments
|
| Novartis Pharmaceuticals | Cosentyx | $81 | 4 payments
|
2021: $342
| AbbVie | Humira | $322 | 21 payments
|
| Incyte | Opzelura | $19 | 1 payment
|
2020: $82
| AbbVie | Skyrizi | $82 | 4 payments
|
2019: $70
| AbbVie | Humira | $49 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $21 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · An Open-Label 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2023 | Their institution | $3,411 |
| Eli Lilly and Company · An Open-Label 24-Week Study To Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis and Skin of Color · 2023 | This clinician | $2 |
Checkups this office reported
4 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 88.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 238 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 2,244 |
| Melanoma: Continuity of Care - Recall SystemAs Medicare defines this measure | 100% | 30 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 99%That's most of the people this applied to. | 2,761 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Did a security review of patient data
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Exempt from electronic case reporting
- Exempt from immunization registry reporting
- Exempt from query of the prescription drug monitoring program (pdmp)
Professional record
- NPI
- 1316972201
- Licence
- CA A84286California A84286: Current · expires 2026-12-31
- Group
- Stanford Health Care · Direct Dermatology Professionals PC
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-11
- NPI last updated
- 2023-10-12
- NPI record certified
- 2023-10-12
This is when the NPI record was last certified, not a medical board exam.